We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+15.12%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$441M
AUM Growth
+$161M
Cap. Flow
+$136M
Cap. Flow %
30.92%
Top 10 Hldgs %
58.73%
Holding
304
New
134
Increased
38
Reduced
45
Closed
43

Top Buys

Rank Stock Value
1
BOXX icon
Alpha Architect 1-3 Month Box ETF
BOXX
+$33.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$28.5M
3
CYTK icon
Cytokinetics
CYTK
+$17.6M
4
ROIV icon
Roivant Sciences
ROIV
+$16.6M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$15.9M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$20.8M
2
RPRX icon
Royalty Pharma
RPRX
+$17.7M
3
VKTX icon
Viking Therapeutics
VKTX
+$10.7M
4
MRK icon
Merck
MRK
+$6.62M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 68.67%
2 Communication Services 1.03%
3 Financials 0.65%
4 Materials 0.49%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
201
CALL
Structure Therapeutics
GPCR
$3.78B
$34.3K 0.01%
+800
New +$33.7K
NGNE icon
202
Neurogene
NGNE
$712M
$33.6K 0.01%
661
-4,744
-88% -$158K
RLYB icon
203
Rallybio
RLYB
$85.8M
$33.2K 0.01%
+2,243
New +$31.3K
TERN
204
DELISTED
Terns Pharmaceuticals
TERN
$32.8K 0.01%
5,000
-8,007
-62% -$52.3K
AMPH icon
205
Amphastar Pharmaceuticals
AMPH
$916M
$30.7K 0.01%
+700
New +$36.2K
LQDA icon
206
Liquidia Corp
LQDA
$8.02B
$29.5K 0.01%
+2,000
New +$27.8K
DSGN icon
207
Design Therapeutics
DSGN
$876M
$29K 0.01%
7,200
+5,200
+260% +$13.9K
QNCX icon
208
Quince Therapeutics
QNCX
$29.5M
$28.4K 0.01%
+134
New +$33.3K
SVRA icon
209
Savara
SVRA
$1.19B
$27.9K 0.01%
+5,600
New +$27.1K
VTYX
210
DELISTED
Ventyx Biosciences
VTYX
$27.5K 0.01%
5,000
-8,000
-62% -$36.6K
PRGO icon
211
Perrigo
PRGO
$1.78B
$25.8K 0.01%
+800
New +$25.2K
VYX icon
212
NCR Voyix
VYX
$1.14B
$25.3K 0.01%
2,000
– –
EQ icon
213
CALL
Equillium
EQ
$133M
$23.1K 0.01%
+10,000
New +$17.4K
ANAB icon
214
AnaptysBio
ANAB
$1.68B
$22.5K 0.01%
+1,000
New +$23.7K
ONCT
215
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$22.2K 0.01%
+2,472
New +$21.7K
CMPX icon
216
Compass Therapeutics
CMPX
$387M
$20.2K ﹤0.01%
+10,206
New +$17.6K
ZYME icon
217
Zymeworks
ZYME
$1.73B
$20K ﹤0.01%
+1,900
New +$21.1K
NATL icon
218
NCR Atleos
NATL
$3.44B
$19.8K ﹤0.01%
1,000
– –
AKBA icon
219
PUT
Akebia Therapeutics
AKBA
$252M
$17.8K ﹤0.01%
+9,700
New +$15.5K
ARWR icon
220
Arrowhead Research
ARWR
$12.4B
$17.2K ﹤0.01%
600
+300
+100% +$9.6K
PMVP icon
221
PMV Pharmaceuticals
PMVP
$63.5M
$17K ﹤0.01%
+10,000
New +$18.7K
AZN icon
222
AstraZeneca
AZN
$250B
$13.6K ﹤0.01%
+100
New +$13.2K
SPLP
223
DELISTED
STEEL PARTNERS HOLDINGS L.P.
SPLP
$13.5K ﹤0.01%
341
– –
NVO
224
Novo Nordisk
NVO
$209B
$12.8K ﹤0.01%
100
-6,250
-98% -$744K
XERS icon
225
Xeris Biopharma Holdings
XERS
$1.37B
$11.4K ﹤0.01%
+5,149
New +$13.3K
7 8
9
10 11

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, ADAR1 Capital Management held 304 positions worth $441M, up 58% from $280M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

ADAR1 Capital Management deployed $136M of net new capital in Q1 2024, opening 134 new positions and adding to 38 existing holdings. Its largest new stake was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, up from 69% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $20.8M trimmed.

  • ADAR1 Capital Management's largest Q1 2024 buy was Alpha Architect 1-3 Month Box ETF: 318,120 shares worth $33.9M.
  • ADAR1 Capital Management added most to Alnylam Pharmaceuticals in Q1 2024, an estimated $28.5M increase.
  • ADAR1 Capital Management's biggest Q1 2024 reduction was Keros Therapeutics, cutting an estimated $20.8M.
  • ADAR1 Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $6.34M.
  • ADAR1 Capital Management's ten largest holdings make up 59% of its $441M portfolio in Q1 2024.
  • ADAR1 Capital Management opened 134 new positions and closed 43 in Q1 2024.
  • ADAR1 Capital Management's portfolio value rose 58% quarter-over-quarter to $441M.

Based on ADAR1 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.